Table 2 Baseline characteristics of the patients who developed Pneumocystis pneumonia a
Patient | Biologic | Age (years) | Sex | RA duration (months)b | Treatment duration (months)c | Pulmonary disease | DM | DAS28 score (ESR) | PSL (mg) | KL-6 (U/ml) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | IFX | 71 | Female | 72 | 10 | (-) | (-) | 6.24 | 2.5 | ND |
2 | IFX | 78 | Female | 79 | 1 | (+) | (-) | 6.99 | 1.0 | 178 |
3 | IFX | 62 | Male | 21 | 20 | (+) | (-) | 7.40 | 2.0 | 893 |
4 | IFX | 78 | Female | 40 | 1 | (+) | (-) | 8.04 | 8.0 | 398 |
5 | IFX | 57 | Male | 5 | 2 | (+) | (-) | 3.38 | 0 | 304 |
6 | ETN | 73 | Male | 2 | 3 | (+) | (-) | 7.20 | 50 | 366 |
7 | ETN | 59 | Female | 252 | 15 | (-) | (-) | 5.60 | 1.0 | 224 |
8 | ETN | 75 | Male | 132 | 5 | (+) | (-) | 6.75 | 5.0 | 624 |
9 | TCZ | 73 | Male | 84 | 8 | (+) | (-) | 7.00 | 10 | 445 |
Mean | 69.5 | 76.3 | 7.2 | 7/9 | 0/9 | 6.51 | 8.83 | 429 |